Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Nature Reviews Drug Discovery 17, 280 (2018). doi:10.1038/nrd.2017.221 Authors: Elizabeth M. Berry-Kravis, Lothar Lindemann, Aia E. Jønch, George Apostol, Mark F. Bear, Randall L. Carpenter, Jacqueline N. Crawley, Aurore Curie, Vincent Des Portes, Farah Hossain, Fabrizio Gasparini, Baltazar Gomez-Mancilla, David Hessl, Eva Loth, Sebastian H. Scharf, Paul P. Wang, Florian Von Raison, Randi Hagerman, Will Spooren & Sébastien Jacquemont Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene, FMR1,
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research